title: Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma.
authors.forename: O
authors.initials: O
authors.lastname: Teronen
authors.forename: M
authors.initials: M
authors.lastname: Laitinen
authors.forename: T
authors.initials: T
authors.lastname: Salo
authors.forename: R
authors.initials: R
authors.lastname: Hanemaaijer
authors.forename: P
authors.initials: P
authors.lastname: Heikkilä
authors.forename: Y T
authors.initials: YT
authors.lastname: Konttinen
authors.forename: T
authors.initials: T
authors.lastname: Sorsa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D015536:Down-Regulation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors